Monashee Investment Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Monashee Investment Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-170,000	Closed	-$1.24M	–	202
2021 Q3	$1.24M	Sell	170,000 -230,000	-58%	-$1.58M	0.23%	95
2021 Q2	$3.44M	Buy	+400,000	New	+$3.41M	0.41%	59
2017 Q3	–	Sell	-25,000	Closed	-$1.35M	–	126
2017 Q2	$1.35M	Buy	+25,000	New	+$1.16M	0.57%	48

Other funds holding FSTX

RCI

Ridgeback Capital Investments Miami Beach, Florida $560K AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Monashee Investment Management's FSTX Position: Q4 2021 in Review

Monashee Investment Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2021, closing a stake of 170,000 shares — an estimated $1.24M sold.

Monashee Investment Management first reported a position in FSTX in Q2 2017 and held it in 3 quarters. The position peaked at $3.44M in Q2 2021. 43 funds tracked by Wall St. Rank hold FSTX as of Q4 2021.

Monashee Investment Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Monashee Investment Management sold 170,000 F-star Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.24M.
Monashee Investment Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
Monashee Investment Management's F-star Therapeutics, Inc. Common Stock position peaked at $3.44M in Q2 2021.
43 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Monashee Investment Management's 13F filing for Q4 2021, filed 7 Feb 2022.